News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
An integrated and agile approach enables the pharmaceutical CDMO industry to simplify manufacturing as it moves from primary care medicines to specialty medicines
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
Price was the key driver for the period
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The availability of advanced SLED dialysis for critical patients, Plasmapheresis, CRRT machines along with ICCU dialysis complete the centre in every way
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
Subscribe To Our Newsletter & Stay Updated
